A recent study has showed that activation of p53 with the MDM2 inhibitor (a key negative regulator of p53) promotes the expression of HERVs-derived dsRNAs in breast cancer cells, thereby inducing the interferon pathway (Zhou et al., 2021). This evidence concerns the gene TP53 and breast carcinoma.